daraxonrasib Clinical Trials (2026): 8 Studies for PDAC & Pancreatic Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
8 daraxonrasib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including PDAC & Pancreatic Cancer) and 3,728 total planned enrollment. 3 Phase 3 daraxonrasib trials and 1 Phase 2 are listed. 7 daraxonrasib clinical trials are actively recruiting at 84 U.S. sites across 29 states. Most recent activity: NCT07492680 (May 2032).
Where to Participate: All daraxonrasib Trial Sites in the U.S. (84 sites across 29 states)
Every actively recruiting daraxonrasibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Alabama Oncology | Birmingham35243 | NCT06881784 | Map |
| CA | MemorialCare Long Beach Medical Center | Long Beach90806 | NCT06881784 | Map |
| CA | University of California, Los Angeles | Los Angeles90404 | NCT07252232 | Map |
| CA | UC IRVINE Health | Orange92868 | NCT06128551 | Map |
| CA | UC Davis Comprehensive Cancer Center | Sacramento95817 | NCT06128551 | Map |
| CA | Stanford Cancer Institute | Stanford94305 | NCT06128551 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT06128551 | Map |
| CT | Hartford Healthcare | Hartford06103 | NCT07252232 | Map |
| CT | Yale University, Smillow Cancer Center | New Haven06519 | NCT06881784 | Map |
| CT | Eastern Connecticut Hematology and Oncology Associates | Norwich06360 | NCT07397338 | Map |
| FL | Florida Cancer Specialists & Research Institute - South | Fort Myers33901 | NCT06881784 | Map |
| FL | BRCR Global | Plantation33322 | NCT06881784 | Map |
| FL | Cancer Care Centers of Breevard | Rockledge32955 | NCT06881784 | Map |
| FL | Florida Cancer Specialists | Sarasota34232 | NCT06128551 | Map |
| FL | Florida Cancer Specialists & Research Institute - North | St. Petersburg33705 | NCT06881784 | Map |
| FL | Cleveland Clinic Martin North | Stuart34994 | NCT06881784 | Map |
| FL | Moffitt Cancer Center and Research Institute | Tampa33612 | NCT06128551 | Map |
| FL | Florida Cancer Specialists & Research Institute - East | West Palm Beach33401 | NCT06881784 | Map |
| GA | University Cancer and Blood Center | Athens30607 | NCT06881784 | Map |
| GA | Piedmont Healthcare, Inc | Atlanta30318 | NCT06881784 | Map |
| IL | Center for Care and Discovery | Chicago60637 | NCT06881784 | Map |
| IN | Community Health Network | Indianapolis46250 | NCT07252232 | Map |
| KS | University of Kansas Medical Center Research Institute, Inc. | Lawrence66045 | NCT07252232 | Map |
| KS | The University of Kansas Cancer Center | Westwood66205 | NCT06881784 | Map |
| MD | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore21287 | NCT07491445 | Map |
| MD | Johns Hopkins University of Medicine | Baltimore21224 | NCT06881784 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins | Baltimore21287 | NCT07252232 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06128551 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07491445 | Map |
| MI | Henry Ford Health | Detroit48202 | NCT06881784 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT06881784 | Map |
| MI | START Midwest | Grand Rapids49546 | NCT06128551 | Map |
| MI | START Midwest | Grand Rapids49546 | NCT07349537 | Map |
| MO | Saint Luke's Cancer Institute | Kansas City64111 | NCT07252232 | Map |
| MO | Washington University School of Medicine - Siteman Cancer Center | St Louis63110 | NCT06881784 | Map |
| MT | St. Vincent Frontier Cancer Center | Billings59102 | NCT06881784 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Henderson89052 | NCT07491445 | Map |
| NH | Dartmouth-Hitchcock Medical Center | Lebanon03756 | NCT06881784 | Map |
| NJ | John Theurer Cancer Center at Hackensack UMC | Hackensack07601 | NCT06881784 | Map |
| NJ | Morristown Medical Center (MMCORC) | Morristown07960 | NCT06881784 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06881784 | Map |
| NY | Columbia University | New York10032 | NCT06128551 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT07252232 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06128551 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06881784 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07252232 | Map |
| NY | NYU Langone Health | New York10032 | NCT06128551 | Map |
| NY | Montefiore Medical Center | The Bronx10461 | NCT06881784 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center at University of North Carolina | Chapel Hill27599 | NCT06881784 | Map |
| OH | TriHealth Cancer & Blood Institute Research | Cincinnati45220 | NCT06881784 | Map |
| OH | Taylor Cancer Research Center | Maumee43537 | NCT06881784 | Map |
| OH | Taylor Cancer Research Center | Maumee43537 | NCT07252232 | Map |
| OH | Taylor Cancer Research Center | Maumee43537 | NCT07491445 | Map |
| OK | University of Oklahoma | Oklahoma City73104 | NCT06128551 | Map |
| OR | Oncology Associates of Oregon PC | Eugene97401 | NCT06881784 | Map |
| PA | Penn State Milton S. Hershey Medical Center | Hershey17033 | NCT06881784 | Map |
| SD | Avera Saint Luke's Hospital | Aberdeen57401 | NCT06881784 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT06881784 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT07252232 | Map |
| TN | Sarah Cannon Research Institue | Nashville37203 | NCT06128551 | Map |
| TN | SCRI Oncology Partners - Tennessee | Nashville37203 | NCT06881784 | Map |
| TN | Tennessee Oncology | Nashville37023 | NCT07397338 | Map |
| TX | Texas Oncology - South Austin | Austin78745 | NCT06881784 | Map |
| TX | NEXT - Dallas | Dallas75039 | NCT07349537 | Map |
| TX | Texas Oncology Dallas | Dallas75251 | NCT06881784 | Map |
| TX | MD Anderson | Houston77030 | NCT06128551 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06881784 | Map |
| TX | NEXT Dallas | Irving75039 | NCT06128551 | Map |
| TX | NEXT Dallas | Irving75039 | NCT07397338 | Map |
| TX | NEXT | San Antonio78229 | NCT07349537 | Map |
| TX | NEXT Oncology | San Antonio78229 | NCT07397338 | Map |
| TX | NEXT Oncology San Antonio | San Antonio78229 | NCT06128551 | Map |
| TX | START - San Antonio | San Antonio78229 | NCT07349537 | Map |
| TX | START Texas | San Antonio78229 | NCT06128551 | Map |
| TX | Texas Oncology - Gulf Coast | The Woodlands77380 | NCT06881784 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06881784 | Map |
| UT | University of Utah, Huntsman Cancer Institute | Salt Lake City94112 | NCT07252232 | Map |
| UT | Utah Cancer Specialists | Salt Lake City84106 | NCT06881784 | Map |
| VA | NEXT - Virginia | Fairfax22031 | NCT07349537 | Map |
| VA | NEXT Oncology Virginia | Fairfax22031 | NCT06128551 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT07397338 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT06881784 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT07252232 | Map |
| WA | Virginia Mason Medical Center | Seattle98101 | NCT07491445 | Map |
daraxonrasib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | not yet recruiting | available | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P1/P2 | 2 | 2 | ||
| P2 | 1 | 1 | ||
| P3 | 3 | 3 | ||
| N/A | 1 | 1 |
Recruiting daraxonrasib clinical trials (7)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | P2 | Solid Tumors | 260 | Jul 2026 |
| NCT06881784 | RASolve 301Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | P3 | NSCLC (Non-small Cell Lung Cancer) | 590 | May 2025 |
| NCT07252232 | RASolute 304Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | P3 | Pancreatic Cancer | 500 | Dec 2025 |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | P1/P2 | Non-Small Cell Lung Cancer (NSCLC) | 534 | Nov 2023 |
| NCT07397338 | ONStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | P1/P2 | Advanced Solid Tumors | 370 | Jan 2026 |
| NCT07491445 | RASolute 303Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | P3 | Pancreatic Cancer | 900 | Mar 2026 |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | P1 | Non-small Cell Lung Cancer (NSCLC) | 574 | Jan 2026 |
daraxonrasib clinical trials by indication
Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07252232 | RASolute 304 | P3 | recruiting | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) |
| NCT07491445 | RASolute 303 | P3 | recruiting | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07492680 | — | P2 | not yet recruiting | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07397338 | ON | P1/P2 | recruiting | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors |
Non-small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07349537 | — | P1 | recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors |
NSCLC (Non-small Cell Lung Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06881784 | RASolve 301 | P3 | recruiting | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) |
Non-Small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06128551 | — | P1/P2 | recruiting | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors |
PDAC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07573215 | RMC-6236 | N/A | available | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma |
daraxonrasib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| RASolve 301 | NCT06881784 | P3 | recruiting | NSCLC (Non-small Cell Lung Cancer) | 590 | — |
| RASolute 304 | NCT07252232 | P3 | recruiting | Pancreatic Cancer | 500 | — |
| RASolute 303 | NCT07491445 | P3 | recruiting | Pancreatic Cancer | 900 | — |
All daraxonrasib trials (8)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | P2 | not yet recruiting | 260 | Bristol-Myers Squibb | Jul 2026 | |
| NCT06881784 | RASolve 301 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | P3 | recruiting | 590 | Revolution Medicines, Inc. | May 2025 |
| NCT07252232 | RASolute 304 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | P3 | recruiting | 500 | Revolution Medicines, Inc. | Dec 2025 |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | P1/P2 | recruiting | 534 | Revolution Medicines, Inc. | Nov 2023 | |
| NCT07397338 | ON | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | P1/P2 | recruiting | 370 | Revolution Medicines, Inc. | Jan 2026 |
| NCT07491445 | RASolute 303 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | P3 | recruiting | 900 | Revolution Medicines, Inc. | Mar 2026 |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | P1 | recruiting | 574 | Revolution Medicines, Inc. | Jan 2026 | |
| NCT07573215 | RMC-6236 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | — | available | 0 | Revolution Medicines, Inc. | — |
daraxonrasib clinical trials: frequently asked questions
- How many daraxonrasib clinical trials are there?
- 8 daraxonrasib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants.
- Are daraxonrasib clinical trials recruiting in 2026?
- Yes — 6 daraxonrasib trials are actively recruiting in 2026, with 84 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is daraxonrasib being studied for?
- daraxonrasib is being studied for PDAC, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, NSCLC and 21 more. The trials are grouped by indication on this page.
- What phase is daraxonrasib in?
- daraxonrasib clinical trials span 3 Phase 3, 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors daraxonrasib clinical trials?
- The lead sponsor across the most daraxonrasib trials is Revolution Medicines, Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming daraxonrasibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: